On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
The Phase III clinical of Butylphthalide Soft Capsules(Trade name: NBP)for the treatment of vascular dementia was officially approved by the Genetics Office in China.